BNTC · Benitec Biopharma Inc. · Documents

Oct 15

Current report 8-K Events of Oct 12

Regulation FD disclosure

Oct 11

Current report 8-K

Entered into a material agreement

Oct 11

Proxy statement PRE 14A

Proxy statement

Oct 8

Current report 8-K

Other events

Sep 26

Current report 8-K

Financial results

Sep 26

Annual report 10-K FY2024, ended Jun 30

Annual report for FY2024

Revenue $0 Net loss $21.75M Diluted EPS -$5.51

Sep 5

Current report 8-K Events of Aug 29

Director or officer change, or executive pay, Shareholder vote results

Jul 29

Proxy statement DEF 14A Meeting Aug 29, 2024

Proxy statement

Jul 19

Proxy statement PRE 14A

Proxy statement

Jul 15

Current report 8-K

Regulation FD disclosure

Jul 1

Current report 8-K Events of Jun 26

Director or officer change, or executive pay

May 16

Registration statement S-1

Registration statement

May 13

Current report 8-K

Financial results

May 13

Quarterly report 10-Q FY2024 Q3, ended Mar 31

Quarterly report for FY2024 Q3

Revenue $0 Net loss $4.28M Diluted EPS -$1.64

Apr 19

Current report 8-K Events of Apr 17

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure

Apr 18

Current report 8-K

Regulation FD disclosure

Mar 8

Current report 8-K Events of Mar 6

Director or officer change, or executive pay

Feb 23

Registration statement S-3

Registration statement

Feb 13

Current report 8-K

Financial results

Feb 13

Quarterly report 10-Q FY2024 Q2, ended Dec 31

Quarterly report for FY2024 Q2

Revenue $0 Net loss $6.8M Diluted EPS -$2.64

Dec 7

Current report 8-K Events of Dec 6

Director or officer change, or executive pay, Shareholder vote results

Nov 30

Current report 8-K

Regulation FD disclosure

Nov 13

Current report 8-K

Financial results

Nov 13

Quarterly report 10-Q FY2024 Q1, ended Sep 30

Quarterly report for FY2024 Q1

Revenue $0 Net loss $5.95M Diluted EPS -$2.76

Oct 20

Proxy statement DEF 14A Meeting Dec 6, 2023

Proxy statement

Oct 20

Proxy statement DEFA14A

Proxy statement

Oct 16

Current report 8-K Events of Oct 11

Director or officer change, or executive pay

Sep 28

Current report 8-K

Other events

Sep 21

Current report 8-K

Financial results

Sep 21

Annual report 10-K FY2023, ended Jun 30

Annual report for FY2023

Revenue $75K ▲ 2.7% Net loss $19.56M Diluted EPS -$14.12

Sep 18

Current report 8-K Events of Sep 13

Director or officer change, or executive pay

Aug 11

Current report 8-K Events of Aug 8

Entered into a material agreement, Other events

Aug 10

Current report 8-K Events of Aug 9

Delisting notice or listing transfer

Aug 7

Registration statement S-1/A

Registration statement

Aug 3

Registration statement S-1/A

Registration statement

Jul 31

Registration statement S-1/A

Registration statement

Jul 25

Current report 8-K

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Regulation FD disclosure, Other events

Jul 7

Registration statement S-1

Registration statement

Jun 26

Current report 8-K

Regulation FD disclosure

Jun 15

Current report 8-K Events of Jun 13

Director or officer change, or executive pay

May 15

Current report 8-K

Financial results

May 15

Quarterly report 10-Q FY2023 Q3, ended Mar 31

Quarterly report for FY2023 Q3

Revenue $54K ▲ 12.5% Net loss $4.4M Diluted EPS -$0.16

Mar 8

Current report 8-K Events of Mar 7

Delisting notice or listing transfer

Feb 13

Current report 8-K

Financial results

Feb 13

Quarterly report 10-Q FY2023 Q2, ended Dec 31

Quarterly report for FY2023 Q2

Revenue $14K ▼ 44.0% Net loss $5.41M Diluted EPS -$0.20

Jan 23

Current report 8-K

Regulation FD disclosure

Dec 13

Registration statement S-1

Registration statement

Dec 12

Current report 8-K Events of Dec 9

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change

Dec 8

Current report 8-K Events of Dec 7

Shareholder vote results

Nov 10

Current report 8-K

Financial results